Display options
Cite
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2006;6(20):1-180
(2006). Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ontario health technology assessment series, 6(20), 1-180.
"Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis." Ontario health technology assessment series vol. 6,20 (2006): 1-180.
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 01. PMID: 23074491; PMCID: PMC3379167.
Copy Download .nbib Format: NLM
Share it on

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 01.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Ontario health technology assessment series

[No authors listed]

PMID: 23074491 PMCID: PMC3379167

Abstract

ISSUE: Systematic reviews and analyses of administrative data were performed to determine the appropriate use of bone mineral density (BMD) assessments using dual energy x-ray absorptiometry (DXA), and the associated trends in wrist and hip fractures in Ontario.

BACKGROUND: DUAL ENERGY X-RAY ABSORPTIOMETRY BONE MINERAL DENSITY ASSESSMENT: Dual energy x-ray absorptiometry bone densitometers measure bone density based on differential absorption of 2 x-ray beams by bone and soft tissues. It is the gold standard for detecting and diagnosing osteoporosis, a systemic disease characterized by low bone density and altered bone structure, resulting in low bone strength and increased risk of fractures. The test is fast (approximately 10 minutes) and accurate (exceeds 90% at the hip), with low radiation (1/3 to 1/5 of that from a chest x-ray). DXA densitometers are licensed as Class 3 medical devices in Canada. The World Health Organization has established criteria for osteoporosis and osteopenia based on DXA BMD measurements: osteoporosis is defined as a BMD that is >2.5 standard deviations below the mean BMD for normal young adults (i.e. T-score <-2.5), while osteopenia is defined as BMD that is more than 1 standard deviation but less than 2.5 standard deviation below the mean for normal young adults (i.e. T-score< -1 & ≥-2.5). DXA densitometry is presently an insured health service in Ontario.

CLINICAL NEED:   BURDEN OF DISEASE: The Canadian Multicenter Osteoporosis Study (CaMos) found that 16% of Canadian women and 6.6% of Canadian men have osteoporosis based on the WHO criteria, with prevalence increasing with age. Osteopenia was found in 49.6% of Canadian women and 39% of Canadian men. In Ontario, it is estimated that nearly 530,000 Ontarians have some degrees of osteoporosis. Osteoporosis-related fragility fractures occur most often in the wrist, femur and pelvis. These fractures, particularly those in the hip, are associated with increased mortality, and decreased functional capacity and quality of life. A Canadian study showed that at 1 year after a hip fracture, the mortality rate was 20%. Another 20% required institutional care, 40% were unable to walk independently, and there was lower health-related quality of life due to attributes such as pain, decreased mobility and decreased ability to self-care. The cost of osteoporosis and osteoporotic fractures in Canada was estimated to be $1.3 billion in 1993.

GUIDELINES FOR BONE MINERAL DENSITY TESTING: With 2 exceptions, almost all guidelines address only women. None of the guidelines recommend blanket population-based BMD testing. Instead, all guidelines recommend BMD testing in people at risk of osteoporosis, predominantly women aged 65 years or older. For women under 65 years of age, BMD testing is recommended only if one major or two minor risk factors for osteoporosis exist. Osteoporosis Canada did not restrict its recommendations to women, and thus their guidelines apply to both sexes. Major risk factors are age greater than or equal to 65 years, a history of previous fractures, family history (especially parental history) of fracture, and medication or disease conditions that affect bone metabolism (such as long-term glucocorticoid therapy). Minor risk factors include low body mass index, low calcium intake, alcohol consumption, and smoking.

CURRENT FUNDING FOR BONE MINERAL DENSITY TESTING: The Ontario Health Insurance Program (OHIP) Schedule presently reimburses DXA BMD at the hip and spine. Measurements at both sites are required if feasible. Patients at low risk of accelerated bone loss are limited to one BMD test within any 24-month period, but there are no restrictions on people at high risk. The total fee including the professional and technical components for a test involving 2 or more sites is $106.00 (Cdn).

METHOD OF REVIEW: This review consisted of 2 parts. The first part was an analysis of Ontario administrative data relating to DXA BMD, wrist and hip fractures, and use of antiresorptive drugs in people aged 65 years and older. The Institute for Clinical Evaluative Sciences extracted data from the OHIP claims database, the Canadian Institute for Health Information hospital discharge abstract database, the National Ambulatory Care Reporting System, and the Ontario Drug Benefit database using OHIP and ICD-10 codes. The data was analyzed to examine the trends in DXA BMD use from 1992 to 2005, and to identify areas requiring improvement. The second part included systematic reviews and analyses of evidence relating to issues identified in the analyses of utilization data. Altogether, 8 reviews and qualitative syntheses were performed, consisting of 28 published systematic reviews and/or meta-analyses, 34 randomized controlled trials, and 63 observational studies.

FINDINGS OF UTILIZATION ANALYSIS: Analysis of administrative data showed a 10-fold increase in the number of BMD tests in Ontario between 1993 and 2005.OHIP claims for BMD tests are presently increasing at a rate of 6 to 7% per year. Approximately 500,000 tests were performed in 2005/06 with an age-adjusted rate of 8,600 tests per 100,000 population.Women accounted for 90 % of all BMD tests performed in the province.In 2005/06, there was a 2-fold variation in the rate of DXA BMD tests across local integrated health networks, but a 10-fold variation between the county with the highest rate (Toronto) and that with the lowest rate (Kenora). The analysis also showed that:With the increased use of BMD, there was a concomitant increase in the use of antiresorptive drugs (as shown in people 65 years and older) and a decrease in the rate of hip fractures in people age 50 years and older.Repeat BMD made up approximately 41% of all tests. Most of the people (>90%) who had annual BMD tests in a 2-year or 3-year period were coded as being at high risk for osteoporosis.18% (20,865) of the people who had a repeat BMD within a 24-month period and 34% (98,058) of the people who had one BMD test in a 3-year period were under 65 years, had no fracture in the year, and coded as low-risk.Only 19% of people age greater than 65 years underwent BMD testing and 41% received osteoporosis treatment during the year following a fracture.Men accounted for 24% of all hip fractures and 21 % of all wrist fractures, but only 10% of BMD tests. The rates of BMD tests and treatment in men after a fracture were only half of those in women.In both men and women, the rate of hip and wrist fractures mainly increased after age 65 with the sharpest increase occurring after age 80 years.

FINDINGS OF SYSTEMATIC REVIEW AND ANALYSIS: SERIAL BONE MINERAL DENSITY TESTING FOR PEOPLE NOT RECEIVING OSTEOPOROSIS TREATMENT: A systematic review showed that the mean rate of bone loss in people not receiving osteoporosis treatment (including postmenopausal women) is generally less than 1% per year. Higher rates of bone loss were reported for people with disease conditions or on medications that affect bone metabolism. In order to be considered a genuine biological change, the change in BMD between serial measurements must exceed the least significant change (variability) of the testing, ranging from 2.77% to 8% for precisions ranging from 1% to 3% respectively. Progression in BMD was analyzed, using different rates of baseline BMD values, rates of bone loss, precision, and BMD value for initiating treatment. The analyses showed that serial BMD measurements every 24 months (as per OHIP policy for low-risk individuals) is not necessary for people with no major risk factors for osteoporosis, provided that the baseline BMD is normal (T-score ≥ -1), and the rate of bone loss is less than or equal to 1% per year. The analyses showed that for someone with a normal baseline BMD and a rate of bone loss of less than 1% per year, the change in BMD is not likely to exceed least significant change (even for a 1% precision) in less than 3 years after the baseline test, and is not likely to drop to a BMD level that requires initiation of treatment in less than 16 years after the baseline test.

SERIAL BONE MINERAL DENSITY TESTING IN PEOPLE RECEIVING OSTEOPOROSIS THERAPY: Seven published meta-analysis of randomized controlled trials (RCTs) and 2 recent RCTs on BMD monitoring during osteoporosis therapy showed that although higher increases in BMD were generally associated with reduced risk of fracture, the change in BMD only explained a small percentage of the fracture risk reduction.Studies showed that some people with small or no increase in BMD during treatment experienced significant fracture risk reduction, indicating that other factors such as improved bone microarchitecture might have contributed to fracture risk reduction.There is conflicting evidence relating to the role of BMD testing in improving patient compliance with osteoporosis therapy.Even though BMD may not be a perfect surrogate for reduction in fracture risk when monitoring responses to osteoporosis therapy, experts advised that it is still the only reliable test available for this purpose.A systematic review conducted by the Medical Advisory Secretariat showed that the magnitude of increases in BMD during osteoporosis drug therapy varied among medications. Although most of the studies yielded mean percentage increases in BMD from baseline that did not exceed the least significant change for a 2% precision after 1 year of treatment, there were some exceptions.

BONE MINERAL DENSITY TESTING AND TREATMENT AFTER A FRAGILITY FRACTURE: A review of 3 published pooled analyses of observational studies and 12 prospective population-based observational studies showed that the presence of any prevalent fracture increases the relative risk for future fractures by approximately 2-fold or more. (ABSTRACT TRUNCATED)

References

  1. Calcif Tissue Int. 2001 Oct;69(4):218-21 - PubMed
  2. J Bone Miner Res. 2006 Apr;21(4):529-35 - PubMed
  3. Joint Bone Spine. 2005 Dec;72(6):562-6 - PubMed
  4. Osteoporos Int. 2000;11(7):556-61 - PubMed
  5. J Clin Endocrinol Metab. 2003 Jul;88(7):3075-81 - PubMed
  6. Osteoporos Int. 2005 May;16(5):568-78 - PubMed
  7. Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):177-86 - PubMed
  8. J Bone Miner Res. 2000 Jan;15(1):24-31 - PubMed
  9. JAMA. 2000 Mar 8;283(10):1318-21 - PubMed
  10. Maturitas. 2000 Oct 31;36(3):173-80 - PubMed
  11. J Clin Endocrinol Metab. 2004 Aug;89(8):3651-5 - PubMed
  12. J Bone Joint Surg Am. 2006 Jan;88(1):25-34 - PubMed
  13. Osteoporos Int. 2000;11(11):977-83 - PubMed
  14. Bone. 2004 Jan;34(1):195-202 - PubMed
  15. Bone. 1996 Mar;18(3 Suppl):203S-207S - PubMed
  16. JAMA. 1999 Aug 18;282(7):637-45 - PubMed
  17. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1563-6 - PubMed
  18. Osteoporos Int. 2005 Mar;16(3):296-301 - PubMed
  19. J Am Geriatr Soc. 2003 Dec;51(12):1740-7 - PubMed
  20. N Engl J Med. 2003 Sep 25;349(13):1216-26 - PubMed
  21. JAMA. 2001 Dec 12;286(22):2815-22 - PubMed
  22. Arch Intern Med. 1998 May 11;158(9):990-6 - PubMed
  23. Bone. 2004 Nov;35(5):1029-37 - PubMed
  24. Osteoporos Int. 2005 Feb;16(2):155-62 - PubMed
  25. N Engl J Med. 2001 May 10;344(19):1434-41 - PubMed
  26. Rheumatol Int. 2004 Mar;24(2):110-3 - PubMed
  27. Osteoporos Int. 2002;13(6):450-5 - PubMed
  28. J Bone Miner Res. 2000 Apr;15(4):721-39 - PubMed
  29. J Bone Miner Res. 2004 Jul;19(7):1172-80 - PubMed
  30. N Engl J Med. 2000 Aug 31;343(9):604-10 - PubMed
  31. Osteoporos Int. 2003 Nov;14(11):895-904 - PubMed
  32. Am J Epidemiol. 2005 Nov 1;162(9):879-86 - PubMed
  33. J Bone Miner Res. 2002 Jun;17(6):1051-6 - PubMed
  34. Osteoporos Int. 2003 Jul;14(6):484-9 - PubMed
  35. CMAJ. 2001 Mar 20;164(6):777-81 - PubMed
  36. Osteoporos Int. 2001;12(11):903-8 - PubMed
  37. Osteoporos Int. 2005 Jul;16(7):737-42 - PubMed
  38. Osteoporos Int. 1997;7(1):52-8 - PubMed
  39. J Bone Joint Surg Am. 2003 Oct;85(10):1936-43 - PubMed
  40. Arch Intern Med. 2002 Feb 25;162(4):450-6 - PubMed
  41. Osteoporos Int. 1997;7(5):488-95 - PubMed
  42. N Engl J Med. 2004 Mar 18;350(12):1189-99 - PubMed
  43. Calcif Tissue Int. 2003 Aug;73(2):133-9 - PubMed
  44. Age Ageing. 1999 Mar;28(2):175-80 - PubMed
  45. BMC Musculoskelet Disord. 2005 Jun 21;6:33 - PubMed
  46. Osteoporos Int. 2005 Jun;16(6):603-9 - PubMed
  47. J Bone Miner Res. 2005 Jan;20(1):100-6 - PubMed
  48. Arthritis Rheum. 1999 Jun;42(6):1246-54 - PubMed
  49. J Rheumatol. 2002 Sep;29(9):1965-74 - PubMed
  50. Osteoporos Int. 2002 Aug;13(8):624-9 - PubMed
  51. Control Clin Trials. 1996 Feb;17(1):1-12 - PubMed
  52. Endocr Pract. 2005 Nov-Dec;11(6):370-5 - PubMed
  53. Osteoporos Int. 2001;12(2):140-51 - PubMed
  54. Menopause. 2003 May-Jun;10(3):228-34 - PubMed
  55. Lancet. 1999 Mar 13;353(9156):878-82 - PubMed
  56. J Bone Miner Res. 2004 Feb;19(2):330-7 - PubMed
  57. Ann Intern Med. 1991 Jun 1;114(11):919-23 - PubMed
  58. J Clin Endocrinol Metab. 2004 Oct;89(10):4879-85 - PubMed
  59. J Clin Endocrinol Metab. 2000 Jan;85(1):219-23 - PubMed
  60. J Med Assoc Thai. 1997 Nov;80(11):731-7 - PubMed
  61. Endocr Rev. 2002 Aug;23(4):552-9 - PubMed
  62. Bone. 1997 Jul;21(1):79-82 - PubMed
  63. Osteoporos Int. 2001;12(5):337-42 - PubMed
  64. J Clin Densitom. 2003 Winter;6(4):307-14 - PubMed
  65. N Engl J Med. 2003 Sep 25;349(13):1207-15 - PubMed
  66. Osteoporos Int. 1999;9(6):469-75 - PubMed
  67. Am J Clin Nutr. 2001 Jan;73(1):118-22 - PubMed
  68. J Bone Miner Res. 2005 Jul;20(7):1185-94 - PubMed
  69. J Musculoskelet Neuronal Interact. 2003 Sep;3(3):189-93 - PubMed
  70. J Am Geriatr Soc. 1993 Nov;41(11):1226-34 - PubMed
  71. JAMA. 1999 Oct 13;282(14):1344-52 - PubMed
  72. Osteoporos Int. 2001;12(10):811-22 - PubMed
  73. Ann Intern Med. 2002 Sep 17;137(6):526-8 - PubMed
  74. Acta Radiol. 2005 May;46(3):306-9 - PubMed
  75. Osteoporos Int. 1999;9(5):455-60 - PubMed
  76. Osteoporos Int. 2004 Oct;15(10):767-78 - PubMed
  77. Int J Clin Pract. 2002 Oct;56(8):620-1 - PubMed
  78. Osteoporos Int. 2000;11(6):493-8 - PubMed
  79. Endocr Rev. 2002 Aug;23(4):529-39 - PubMed
  80. Osteoporos Int. 2003 Aug;14(8):672-6 - PubMed
  81. Osteoporos Int. 1999;9(1):45-54 - PubMed
  82. BMC Musculoskelet Disord. 2004 Apr 06;5:11 - PubMed
  83. Arch Intern Med. 2005 Aug 8-22;165(15):1743-8 - PubMed
  84. BMC Musculoskelet Disord. 2005 Jul 11;6:39 - PubMed
  85. J Bone Miner Res. 2002 Jan;17(1):1-10 - PubMed
  86. Bone. 2003 Jan;32(1):78-85 - PubMed
  87. J Am Geriatr Soc. 2004 Sep;52(9):1479-86 - PubMed
  88. BMC Fam Pract. 2006 Feb 07;7:7 - PubMed
  89. Calcif Tissue Int. 1989 Dec;45(6):327-30 - PubMed
  90. Osteoporos Int. 2003 Jan;14(1):61-8 - PubMed
  91. Am J Prev Med. 2004 Jun;26(5):436-42 - PubMed
  92. QJM. 2004 Sep;97(9):569-74 - PubMed
  93. Lancet. 2002 Jun 1;359(9321):1929-36 - PubMed
  94. J Intern Med. 2003 Nov;254(5):486-93 - PubMed
  95. Bone. 2004 Aug;35(2):375-82 - PubMed
  96. J Clin Invest. 1998 Oct 15;102(8):1627-33 - PubMed
  97. J Clin Endocrinol Metab. 2002 Apr;87(4):1586-92 - PubMed
  98. CMAJ. 1997 Nov 15;157(10):1357-63 - PubMed
  99. Endocr Rev. 2002 Aug;23(4):540-51 - PubMed
  100. Bone. 2002 Jan;30(1):251-8 - PubMed
  101. Endocr Rev. 2002 Aug;23(4):524-8 - PubMed
  102. Maturitas. 2004 Jul 15;48(3):271-87 - PubMed
  103. Osteoporos Int. 2005 Nov;16(11):1330-8 - PubMed
  104. Bone. 2005 Mar;36(3):387-98 - PubMed
  105. Lancet. 1993 Jan 9;341(8837):72-5 - PubMed
  106. Lancet. 2005 Dec 17;366(9503):2068-70 - PubMed
  107. Osteoporos Int. 2002 Mar;13(3):205-10 - PubMed
  108. J Bone Miner Res. 2004 Jun;19(6):893-9 - PubMed
  109. N Engl J Med. 1998 Sep 10;339(11):733-8 - PubMed
  110. Osteoporos Int. 2005 Aug;16(8):977-82 - PubMed
  111. Endocr Rev. 2002 Aug;23(4):517-23 - PubMed
  112. Osteoporos Int. 1998;8(6):563-9 - PubMed
  113. CMAJ. 2004 May 25;170(11):1665-7 - PubMed
  114. J Clin Endocrinol Metab. 2000 Sep;85(9):3069-76 - PubMed
  115. J Bone Miner Res. 2005 Jun;20(6):898-905 - PubMed
  116. J Clin Endocrinol Metab. 2005 Apr;90(4):1998-2004 - PubMed
  117. J Clin Densitom. 2005 Winter;8(4):371-8 - PubMed
  118. Osteoporos Int. 2004 Nov;15(11):897-902 - PubMed
  119. Ann Intern Med. 1993 Nov 15;119(10):963-8 - PubMed
  120. J Clin Endocrinol Metab. 2000 Jan;85(1):231-6 - PubMed
  121. Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):208-13 - PubMed
  122. Osteoporos Int. 2001;12(2):85-90 - PubMed
  123. Climacteric. 2005 Sep;8(3):251-62 - PubMed
  124. Osteoporos Int. 2005 Dec;16(12):2185-94 - PubMed
  125. Arch Intern Med. 2001 May 28;161(10):1309-12 - PubMed
  126. Osteoporos Int. 2003 Jul;14(6):520-4 - PubMed
  127. CMAJ. 2002 Nov 12;167(10 Suppl):S1-34 - PubMed
  128. J Clin Densitom. 2004 Fall;7(3):255-61 - PubMed
  129. Osteoporos Int. 2005 Dec;16(12):1525-37 - PubMed
  130. J Bone Miner Res. 2003 Jul;18(7):1254-60 - PubMed
  131. Osteoporos Int. 2006;17(9):1337-45 - PubMed
  132. Endocrinol Metab Clin North Am. 2002 Sep;31(3):659-79, xii - PubMed
  133. Endocr Rev. 2002 Aug;23(4):560-9 - PubMed
  134. Endocr Rev. 2002 Aug;23(4):508-16 - PubMed
  135. J Bone Miner Res. 2005 Dec;20(12):2097-104 - PubMed
  136. Osteoporos Int. 1998;8(4):373-8 - PubMed
  137. Osteoporos Int. 2000;11(10):866-70 - PubMed
  138. Arch Intern Med. 2005 Aug 8-22;165(15):1762-8 - PubMed
  139. J Bone Miner Res. 1997 Nov;12(11):1761-8 - PubMed
  140. Curr Osteoporos Rep. 2004 Jun;2(2):41-6 - PubMed
  141. Osteoporos Int. 2005 Sep;16(9):1079-85 - PubMed
  142. Osteoporos Int. 2003 Apr;14(2):123-9 - PubMed
  143. Endocr Rev. 2002 Aug;23(4):570-8 - PubMed
  144. Can Assoc Radiol J. 2005 Jun;56(3):178-88 - PubMed
  145. J Clin Densitom. 2002 Winter;5(4):435-45 - PubMed
  146. BMC Musculoskelet Disord. 2005 Sep 05;6:47 - PubMed
  147. Ann Intern Med. 1998 Jun 15;128(12 Pt 1):996-9 - PubMed
  148. Osteoporos Int. 2001 Dec;12(12):989-95 - PubMed
  149. Osteoporos Int. 1999;10(4):259-64 - PubMed
  150. Osteoporos Int. 2000;11(3):192-202 - PubMed
  151. Can J Surg. 1996 Apr;39(2):105-11 - PubMed
  152. Osteoporos Int. 2000;11(10):897-904 - PubMed
  153. Clin Rheumatol. 1997 Jun;16(4):354-60 - PubMed
  154. J Clin Endocrinol Metab. 1997 Feb;82(2):620-8 - PubMed
  155. Rheumatol Int. 2006 Mar;26(5):427-31 - PubMed
  156. CMAJ. 2000 Oct 3;163(7):819-22 - PubMed
  157. Osteoporos Int. 2004 Apr;15(4):323-8 - PubMed
  158. J Clin Endocrinol Metab. 2004 Mar;89(3):1117-23 - PubMed
  159. J Intern Med. 2004 Apr;255(4):503-11 - PubMed
  160. J Clin Endocrinol Metab. 2004 Jul;89(7):3261-9 - PubMed
  161. J Clin Endocrinol Metab. 2000 May;85(5):1895-900 - PubMed
  162. Osteoporos Int. 2005 Sep;16(9):1156-60 - PubMed
  163. Osteoporos Int. 2003 Jan;14(1):19-26 - PubMed
  164. J Clin Endocrinol Metab. 1997 Jan;82(1):265-74 - PubMed
  165. Osteoporos Int. 2003 Nov;14(11):889-94 - PubMed
  166. Semin Arthritis Rheum. 2006 Apr;35(5):293-305 - PubMed
  167. JAMA. 1998 Dec 23-30;280(24):2077-82 - PubMed
  168. Osteoporos Int. 2003 Apr;14(2):171-8 - PubMed
  169. J Bone Miner Res. 2000 Jun;15(6):993-1000 - PubMed
  170. J Clin Endocrinol Metab. 2002 Jun;87(6):2792-7 - PubMed
  171. Ann Intern Med. 2004 Sep 7;141(5):366-73 - PubMed
  172. J Bone Miner Res. 2000 Aug;15(8):1526-36 - PubMed
  173. Osteoporos Int. 2005 Jul;16(7):799-804 - PubMed
  174. Bone. 2002 Jul;31(1):57-61 - PubMed
  175. Osteoporos Int. 2001;12(4):271-8 - PubMed
  176. Osteoporos Int. 2005 Oct;16(10):1184-92 - PubMed
  177. J Clin Endocrinol Metab. 2004 Feb;89(2):626-31 - PubMed
  178. Chest. 2006 Oct;130(4):1082-8 - PubMed
  179. Am J Med. 2004 Oct 15;117(8):549-55 - PubMed
  180. J Bone Miner Res. 2001 Mar;16(3):581-8 - PubMed
  181. Osteoporos Int. 2004 Jun;15(6):439-46 - PubMed
  182. Osteoporos Int. 2003 Oct;14(10):793-800 - PubMed
  183. Osteoporos Int. 2005 Aug;16(8):963-8 - PubMed
  184. Am J Med. 1993 Jun;94(6):646-50 - PubMed
  185. Osteoporos Int. 2004 Dec;15(12):1003-8 - PubMed
  186. Osteoporos Int. 2004 Jan;15(1):32-7 - PubMed
  187. Osteoporos Int. 2004 Mar;15(3):175-9 - PubMed
  188. Osteoporos Int. 2005 Feb;16(2):208-15 - PubMed
  189. Osteoporos Int. 1998;8(5):468-89 - PubMed
  190. J Bone Miner Res. 2005 Aug;20(8):1349-55 - PubMed
  191. Ann Intern Med. 2006 May 16;144(10):753-61 - PubMed
  192. J Clin Densitom. 2006 Jul-Sep;9(3):281-6 - PubMed
  193. Osteoporos Int. 1997;7(4):390-406 - PubMed
  194. Yonsei Med J. 2005 Dec 31;46(6):750-8 - PubMed
  195. Am J Epidemiol. 2003 Dec 15;158(12):1132-8 - PubMed
  196. J Intern Med. 2005 Apr;257(4):374-84 - PubMed
  197. J Clin Endocrinol Metab. 2002 Oct;87(10):4528-35 - PubMed
  198. Osteoporos Int. 2004 Jun;15(6):483-8 - PubMed
  199. Osteoporos Int. 1999;9(5):461-8 - PubMed
  200. Arch Intern Med. 2005 Nov 14;165(20):2414-9 - PubMed
  201. Osteoporos Int. 2005 Jul;16(7):842-8 - PubMed
  202. Osteoporos Int. 2005 Mar;16 Suppl 2:S44-53 - PubMed
  203. Osteoporos Int. 2000;11(5):393-9 - PubMed
  204. Am J Med. 2002 Mar;112(4):281-9 - PubMed
  205. Clin Geriatr Med. 2003 May;19(2):361-70 - PubMed
  206. Osteoporos Int. 2006;17(6):914-21 - PubMed
  207. Osteoporos Int. 2000;11(1):83-91 - PubMed
  208. Ann Rheum Dis. 2006 Jan;65(1):87-92 - PubMed
  209. CMAJ. 2006 Jul 4;175(1):52-9 - PubMed
  210. N Engl J Med. 2005 Aug 11;353(6):566-75 - PubMed

Publication Types